In 2025, the Department of Justice’s National Health Care Fraud Takedown led to criminal charges against 324 defendants and $14.6 billion in intended losses.

I recently spoke with MedTech Dive about the Trump administration’s heightened focus on fraud involving genetic testing, an area that has become a growing concern for federal regulators. I explained in the article that a significant portion of that enforcement activity was tied to genetic testing and telemedicine, which together accounted for more than $1.17 billion in alleged fraudulent Medicare claims. When that level of enforcement is viewed alongside rising spending in this space, it helps explain why genetic testing is now under increased scrutiny.

That attention is continuing this year. In late February, the Centers for Medicare and Medicaid Services issued a request for information seeking input on potential regulatory changes designed to reduce fraud in laboratory testing, including molecular and genetic tests. I discussed how CMS is specifically exploring whether to expand the use of the Molecular Diagnostic Services (MolDX) program, which is not currently applied consistently across all states. In the article, I emphasized that if Medicare moves toward broader adoption of MolDX, it will be important for the government to ensure the program is implemented with clear standards, consistency, and appropriate oversight nationwide.

For a deeper look at the enforcement trends and what they could mean for genetic testing and laboratory providers, I encourage you to read the full article, “Genetic tests come under scrutiny in Trump administration’s fraud crackdown,” published by MedTech Dive on March 12 and republished by Healthcare Dive.